TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).

N Boku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.